Healthside Partners to Acquire Quorum Health Assets in Nonprofit Transition
Quorum Health, a private‑equity‑owned hospital operator, announced a definitive agreement to transfer its assets to nonprofit system Healthside Partners. Healthside will acquire the assets without assuming liabilities, with the transition slated to close in the fall and includes over $300 million in planned capital investments. The deal will convert Quorum to a nonprofit entity, unlocking tax‑exempt funding and 340B drug discount benefits.
Macmillan Cancer Support Launches Macmillan Ventures VC Fund to Back Cancer Care Innovations
Macmillan Cancer Support has launched Macmillan Ventures, a new venture capital fund backed by donations from philanthropists and organisations to invest in cancer treatment innovations. The fund follows the charity’s prior investments of over $4.4 million since 2023, including participation in...
Enhanced Group Launches IPO, Debuts on Public Markets
Enhanced Group, a digital health company, announced its public market debut via an IPO on May 21, 2026, marking a milestone for the sector. The listing follows the company's launch of a high‑profile athlete event and its telehealth platform Live...
Eli Lilly to Acquire Engage Biologics for Up to $202M
Eli Lilly announced it will acquire Engage Biologics Inc. in a transaction valued at up to $202 million. The deal brings Engage's non‑viral DNA delivery platform into Lilly's genetic medicines pipeline, enhancing its gene‑therapy capabilities. The acquisition is part of...
Efferon Secures €2.5M ($2.75M) Seed Round to Grow Blood‑purification Platform
Biotech firm Efferon closed a €2.5 million seed round led by private investors from the DACH region. The funding will support the European commercial rollout of its hemoadsorption device Efferon LPS and the construction of a new EU production facility, expanding...
Conexeu Sciences Inc. (CNXU) Launches IPO on Nasdaq, Raising Capital for Regenerative Medicine
Reno‑based Conexeu Sciences Inc. (Nasdaq: CNXU) completed its initial public offering and began trading on Nasdaq on May 21, 2026, issuing 25.3 million shares. The biotech firm, focused on regenerative tissue scaffolds such as its B.R.E.A.S.T.™ product, will use the proceeds to advance...
Innovaccer Acquires CaduceusHealth to Expand AI Revenue Cycle Platform
Innovaccer Inc. announced the completion of its asset acquisition of CaduceusHealth, adding the latter’s U.S.-based revenue cycle management network serving nearly 4,000 providers and $5 billion in gross patient charges. The deal expands Innovaccer’s Flow platform into a full‑stack AI‑native revenue...
Parabilis Medicines Announces Plans for IPO
Parabilis Medicines, the biotech spin‑out from Greg Verdine’s Harvard lab, announced its intention to go public, aiming to become the 12th drug developer to list on the exchange. The announcement follows a Regeneron deal the day before, underscoring rising biotech...
Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta
Qualtrics has completed its acquisition of Press Ganey Forsta for $6.75 billion, creating the largest AI dataset for human experiential context in healthcare. The deal expands Qualtrics’ employee experience platform into the healthcare sector, adding 41,000 facility clients and strengthening its...
Gaia Secures $100M Debt Facility From Viola Credit
New York‑based fertility startup Gaia announced on May 20 2026 that it has closed a $100 million debt facility with Viola Credit. The financing will be used to scale its AI‑driven outcome‑based IVF financing platform across the United States. The deal follows a...
Genesis Molecular AI Secures $120M Partnership with Incyte
Genesis Molecular AI announced a $120 million partnership with biotech giant Incyte, comprising $80 million in upfront cash and a $40 million equity investment. The collaboration will expand AI‑driven drug discovery across oncology, hematology and inflammation, with potential milestones that could push the...
Oorja Bio Secures $30M Series A Funding From Westlake
Oorja Bio, a new biotech targeting idiopathic pulmonary fibrosis, announced the closing of a $30 million Series A round on Tuesday. The round was led entirely by Westlake, providing capital to advance its drug development pipeline after the success of...
LifeSigns Secures Undisclosed Investment From HealthQuad
Indian remote monitoring startup LifeSigns raised an undisclosed amount of funding from healthcare venture capital firm HealthQuad to fuel its global expansion across Southeast Asia and Gulf markets. The investment will support scaling of its AI‑powered platform that combines wearables,...
Mentari Therapeutics to Go Public via $421M Reverse Merger with InMed, Raising $290M Private Placement
Mentari Therapeutics announced a reverse merger with public shell InMed Pharmaceuticals, creating a combined company under the Mentari name with a pro forma equity value of about $421 million. The transaction includes a concurrent private placement raising roughly $290 million,...
Boston Scientific Buys $1.5B Stake in TAVR Developer MiRus
Boston Scientific announced it has invested $1.5 billion to acquire a 34% equity stake in MiRus, a developer of a balloon‑expandable transcatheter aortic valve replacement (TAVR) system. The deal includes an exclusive option for Boston Scientific to purchase the remaining business...